Retro Biosciences valued at $1.8b to accelerate longevity research - Longevity.Technology
Summary
Retro Biosciences has raised a new funding round that values the longevity startup at $1.8 billion. The company is advancing therapies aimed at extending human healthspan, including gene therapies and cell replacement technologies. It is also running its first clinical trial for an oral therapeutic intended to improve clearance of protein aggregates linked to Alzheimer’s disease. Early safety results look encouraging, and Retro expects to share initial trial data in August 2026. The financing marks a shift from basic longevity research toward early human testing.
Funding
Amount
-
Total raised
Date
May 22, 2026
Announcement date
Investors
-
Lead investors
Company
https://retro.bio
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected